HIV Infections Clinical Trial
Official title:
Aging & HIV/AIDS Neurocognitive Sequelae and Functional Consequences
While the numbers of HIV infected veterans under the age of 50 are declining, the percentage
of HIV infected veterans over the age of 50 is increasing with the largest percentage
increases in the 50-59 age group and the 70+ age group. With increasing incidence rates of
new cases among individuals over 50 years of age and the longer life expectancies of the
current HIV-infected population, it becomes increasingly important to better understand the
impact of the aging process on the clinical and behavioral manifestations of HIV/AIDS.
The project seeks to determine the effect of age on neuropsychological performance in HIV+
persons. This objective seeks to determine the degree to which older age represents an
independent risk factor for neuropsychological impairment in HIV infected persons, with a
particular emphasis on those cognitive processes that are preferentially impacted by both
the normal aging process as well as HIV infection. Additionally, another aim of the study is
to determine the impact of neuropsychological decline on everyday functional abilities among
older vs. younger HIV+ adults. This objective seeks to determine the effects of advancing
age and neuropsychological impairment on the ability of HIV+ persons to discharge more
demanding requirements of independent living (e.g., driving, financial management,
medication adherence). The project will last for a duration of 5 years.
Over the past several years the HIV epidemic has changed from a disease primarily of
younger, gay/bisexual, Caucasian men to one increasingly affecting people of color, women,
and, of specific relevance to this application, the older adult. Indeed, the number of AIDS
cases in individuals over the age of 50 has more than tripled over the last several years,
with the CDC now estimating that in the United States 15% of all patients with AIDS are over
age 50.1 There is reason to believe that the incidence, clinical manifestations and course
of HIV-associated CNS dysfunction may differ as a function of age. Since the mid 1980's VA
has been at the vanguard of institutions engaged in research and clinical care of
HIV-infected adults. With specific regard to the issue of aging and HIV, HIV-infected
veterans have tended to be significantly older than patients drawn from the general
community. For example, at the West Los Angeles VA 303 of the 583 (52%) HIV-infected
patients being followed by the Infectious Disease clinic are over the age of 50. Across the
entire VA system, there are nearly twice as many HIV infected veterans over the age of 70
than under 30 years of age. 2 Yet, the vast majority of research conducted to date has been
on younger adults - the degree to which such data will generalize to the older veteran
population is unclear. Also unclear is whether advancing age confers an independent risk for
cognitive impairment in HIV-infected persons. Additionally, the functional impact (i.e.,
impact on daily functioning such as driving ability, financial management, or medication
adherence) of cognitive impairment in this group remains unknown. Exploratory studies
performed in the applicants' laboratory have provided preliminary support for the hypothesis
that advancing age will potentiate the deleterious neurocognitive effects of HIV infection.
Given the "graying" of the HIV epidemic, particularly among the veteran population, research
examining neurocognition among older HIV-infected veterans as well as the functional "real
world" impact of such deficits is of great relevance to the VA mission. The results from
this study could provide important insights into interactions of age and HIV disease, and
will identify targets for intervention in advance of the burgeoning population of older
infected persons.
SPECIFIC OBJECTIVES AND HYPOTHESES
Objective 1. To Determine the Effect of Age on Neuropsychological Performance in HIV+
Persons This objective seeks to determine the degree to which older age represents an
independent risk factor for neuropsychological impairment in HIV infected persons, with a
particular emphasis on those cognitive processes that are preferentially impacted by both
the normal aging process as well as HIV infection.
Hypothesis 1.1 Controlling for potential confounding factors such as substance use and
length of infection, there will be an interaction between effects of age and HIV serostatus
on neuropsychological performance, and this will be evident both cross-sectionally and
longitudinally. Specifically, we expect to find that older HIV+ individuals will exhibit
greater rates of neuropsychological impairment (using age-corrected test norms) than younger
HIV+ persons. Neurocognitive functions subserved by frontal-subcortical systems that are
sensitive to the effects of both aging and HIV infection (learning, motor and psychomotor
speed, executive function) will be disproportionately affected among the older HIV+
participants. While the synergistic effects of HIV and age will be evident on a cross
sectional basis, they will be most pronounced when examined longitudinally over the course
of the study.
;
Observational Model: Case Control, Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05454514 -
Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS
|
N/A | |
Completed |
NCT03760458 -
The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age
|
Phase 1/Phase 2 | |
Completed |
NCT03067285 -
A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study
|
Phase 4 | |
Completed |
NCT03141918 -
Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS
|
N/A | |
Recruiting |
NCT04579146 -
Coronary Artery Disease (CAD) in Patients HIV-infected
|
||
Completed |
NCT06212531 -
Papuan Indigenous Model of Male Circumcision
|
N/A | |
Active, not recruiting |
NCT03256422 -
Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients
|
Phase 3 | |
Completed |
NCT03256435 -
Retention in PrEP Care for African American MSM in Mississippi
|
N/A | |
Completed |
NCT00517803 -
Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies
|
N/A | |
Active, not recruiting |
NCT03572335 -
Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
|
||
Completed |
NCT04165200 -
Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV
|
N/A | |
Recruiting |
NCT03854630 -
Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection
|
Phase 4 | |
Terminated |
NCT03275571 -
HIV, Computerized Depression Therapy & Cognition
|
N/A | |
Completed |
NCT02234882 -
Study on Pharmacokinetics
|
Phase 1 | |
Completed |
NCT01618305 -
Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission
|
Phase 4 | |
Recruiting |
NCT05043129 -
Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
|
||
Not yet recruiting |
NCT05536466 -
The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine
|
N/A | |
Recruiting |
NCT04985760 -
Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy
|
Phase 1 | |
Completed |
NCT05916989 -
Stimulant Use and Methylation in HIV
|
||
Terminated |
NCT02116660 -
Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)
|
Phase 2 |